AZD5156 for COVID-19: real-time analysis

Download Image

Post

c19early.org

AZD5156 for COVID-19

1 study with 57 patients

Serious outcome risk

AZD5156

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 AZD5156 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−139%

Mortality (1)−139%

RCTs (1)−139%

Prophylaxis (1)−139%

00.511.5+

← AZD5156
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Recent:

Haidar.


Jun 18	Haidar et al., NCT05648110	Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)
Jun 18	139% higher mortality (p=1). RCT 57 patients showing no significant differences with AZD5156 (sipavibart + cilgavimab).